...
首页> 外文期刊>African journal of urology >Efficacy and safety of silodosin, vardenafil versus silodosin in combination with vardenafil as a medical expulsive therapy for distal ureteric stones: a prospective randomized double-blind study
【24h】

Efficacy and safety of silodosin, vardenafil versus silodosin in combination with vardenafil as a medical expulsive therapy for distal ureteric stones: a prospective randomized double-blind study

机译:硅二辛的疗效和安全性,Vardenafil对硅牛蛋白与Vardenafil相结合,作为远端输尿管结合的医学驱逐治疗:一项前瞻性随机双盲研究

获取原文

摘要

Background:Urolithiasis is considered one of the most common diseases in urological practice. Its prevalence is about 1% to 15% with 30?years old as the peak age of incidence. Medical expulsive therapy (MET) has been used as a conservative treatment for patients with ureteral stones. Nitrergic fibers have been identified to have a relaxant effect on the distal ureteral smooth musculature. The objective of our study was to evaluate the efficacy and safety of the combination of silodosin and vardenafil as a medical expulsive therapy in comparison with each drug alone.MethodsOne hundred and two male patients with uncomplicated distal ureteric stone 6–10?mm were enrolled in the study. The patients were randomly divided into 3 equal groups, and each one consists of 34 patients. Group I received silodosin 8?mg once daily, group II vardenafil 5?mg once daily and group III combination of silodosin 8?mg and vardenafil 5?mg once daily. The treatment was given for all the patients until stone expulsion or a maximum of 4?weeks. The primary endpoint was the stone expulsion rate, and the secondary endpoints were time to stone expulsion, number of hospital visits for pain, amount of analgesic required and side effects associated with MET.ResultsOur study showed that the stone expulsion rate was higher in combination?=?90.0% than silodosin?=?76.7% and vardenafil groups?=?60.0% (P?=?0.025), the time to stone expulsion was significantly shorter in combination?=?11.23?±?3.14 than silodosin?=?12.50?±?1.66 and vardenafil groups 14.67?±?1.24?days (P?
机译:背景:尿路结石被认为是泌尿外科实践中最常见的疾病之一。它的患病率约为1%至15%与30?岁为发病高峰年龄。医疗推斥疗法(MET)已被用作治疗输尿管结石保守治疗。氮能纤维已被鉴定为具有在远端输尿管平滑肌一个松弛作用。我们研究的目的是评估与每种药物alone.MethodsOne一百零二名男性患者无并发症的远端输尿管结石6-10?毫米招收了比较西洛多辛和伐地那非作为医疗推斥治疗相结合的疗效和安全性研究。将患者随机分为3个相等的组,而且每一个是由34例患者。组I西洛多辛8接收?每日一次毫克,组II伐地那非5?毫克每日一次和组III的西洛多辛8?mg和伐地那非5?毫克每日一次组合。治疗给予所有患者直至结石排出或最多4?周。主要终点是在结石排出率,次要终点是时间结石排出,疼痛医院就诊的人数,与MET.ResultsOur研究相关的镇痛要求和副作用量表明,结石排出率为组合高? =?90.0比西洛多辛%?=?76.7%和伐地那非组?=?60.0%( P 的?=?0.025),时间到结石排出在组合显著短?=?11.23?± 3.14比西洛多辛?=?12.50?±1.66和伐地那非组14.67?±1.24?天( P 的<??0.01),对疼痛医院就诊的数目是三个之间统计学显著基(西洛多辛1.35?±?0.9,伐地那非1.65?±1.09和组合组1.02?±0.80)( P 的?=?0.038)和在组合313.6需要较少量的镇痛?±? 2.85.5比西洛多辛613.44?±?483.62和伐地那非组716.97?±?685.3( P 的?=?0.008)。有所研究群体至于药物副作用除了逆行性射精间无显著差异(西洛多辛和组合?=?86.7%比伐地那非组?=?0.0%)( P 的<??0.05 ),增加勃起(组合?=?26.7%,伐地那非?=?23.3%和西洛多辛组?=?0%)( P 的?=?0.010)伐地那非在用西洛多辛组合。结论处方是安全的,比西洛多辛或伐地那非单独作为MET更有效。

著录项

相似文献

  • 外文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号